January 28th 2025
The FDA-recognized fiber ingredient received certification as low FODMAP, highlighting its use for consumers following IBS dietary recommendations.
Branded probiotic strain ibSium may support symptoms of IBS, says recent study
February 7th 2020A clinical study recently published in the Journal of Colorectal Disease found that the proprietary probiotic strain Saccharomyces cerevisiae CNCM I-3856 improved abdominal pain and bowel habits in subjects with irritable bowel syndrome.
LactoSpore probiotic from Sabinsa granted new patent for depression symptoms in IBS patients
December 24th 2019Sabinsa (East Windsor, NJ) has been granted U.S. patent US10166261 for the administration of Bacillus coagulans MTCC 5856 (LactoSpore) at a dose of 2 billion CFU per day as a way to manage dementia and dementia-related sleep disorders, presented as symptoms of major depressive disorder, in humans with IBS.